EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections
- 27 April 2016
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (9) , 3943-3950
Abstract
Purpose Epidermal growth factor receptor (EGFR) inhibitors are approved for use as targeted chemotherapeutic agents against multiple solid-organ malignancies. The most common side effect associated with EGFR inhibitor therapy is a papulopustular eruption, which can easily be confused with bacterial folliculitis. In this study, we examine the relative timing and location of the EGFR-induced papulopustular eruption compared to the associated bacterial superinfections. Methods In this retrospective chart review, patients enrolled in our institution’s IRB-approved prospective registry of cutaneous reactions to chemotherapy were screened for inclusion. All patients who received an EGFR inhibitor and developed either a papulopustular eruption or bacterial superinfection at some point during treatment were included. Results Of the 157 patients who met inclusion criteria, 36 (23 %) developed bacterial superinfections at some point during EGFR therapy. Papulopustular eruptions developed in a highly predictable time course, with a mean time to onset of 1.5 weeks and mean duration of 9.4 weeks. Bacterial superinfections occurred at widely variable time points during therapy with a mean time to onset of 27.7 weeks. Papulopustular eruptions much more frequently affected the face (97 %), chest (75 %), and back (61 %), while bacterial superinfections occurred more commonly on the upper extremity (64 %), lower extremity (47 %), and abdomen (39 %). Conclusions The EGFR inhibitor-induced papulopustular eruption has a stereotypical time course and occurs in a characteristic distribution affecting the central face, upper chest, and back. Bacterial superinfections more frequently affect the extremities, abdomen, and groin and may occur at any point during EGFR therapy.Keywords
Funding Information
- None
This publication has 29 references indexed in Scilit:
- Epidermal EGFR Controls Cutaneous Host Defense and Prevents InflammationScience Translational Medicine, 2013
- Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitorsJournal of Cutaneous Pathology, 2013
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEuropean Journal of Cancer, 2010
- Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic CooperationClinical Colorectal Cancer, 2008
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Blockade of the EGF Receptor Induces a Deranged Chemokine Expression in Keratinocytes Leading to Enhanced Skin InflammationThe American Journal of Pathology, 2003
- The EGF receptor - an essential regulator of multiple epidermal functions.2000
- Targeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant PhenotypeScience, 1995
- Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human SkinJournal of Investigative Dermatology, 1990